Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

• Sponsor: University Hospital Inselspital, Berne (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05236283
• Collaborator: (none)
• Enrollment: 395
• Location: 1
• Anticipated Duration (Days): 28
• Patients Per Site Per Month: 429.4

Study Details

Study Description

Brief Summary

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Condition or Disease	Intervention/Treatment	Phase
Bacteremia	Diagnostic Test: Blood Culture

Study Design

• Study Type: Observational
• Anticipated Enrollment: 395 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study
• Anticipated Study Start Date: Feb 1, 2022
• Anticipated Primary Completion Date: Mar 1, 2022
• Anticipated Study Completion Date: Mar 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Bern ICU	Diagnostic Test: Blood Culture; Blood Culture
Lausanne ICU	Diagnostic Test: Blood Culture; Blood Culture

Outcome Measures

Primary Outcome Measures

1. Antibiotic Treatment Duration [Hospital discharge, expected to be on average ca. 15-20 days]

   Days of adequate antibiotic treatment in Patients with Bacteremia

Secondary Outcome Measures

1. Days of ICU stay [ICU discharge, expected to be on average ca. 5-15 days]

   Days of ICU Stay in Patients with Bacteremia

2. Days of hospital stay [Hospital discharge, expected to be on average ca. 15-25 days]

   Days of Inhospital Stay in Patients with Bacteremia

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:

1. was treated at the ICU/IMC at the time of blood culture collection;

2. or has been admitted to ICU/IMC in the 48 hours after blood culture collection

Exclusion Criteria:

1. Patient has a single positive blood culture with a common contaminant organism:

• coagulase negative staphylococci;

• Bacillus spp.;

• Corynebacterium spp.;

• Propionibacterium spp.;

• Aerococcus spp.;

• Micrococcus spp.

1. Explicit documentation that the patient does not want to participate in any study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Departement of Intensive Care Medicine	Bern		Switzerland

Sponsors and Collaborators

• University Hospital Inselspital, Berne

Investigators

• Principal Investigator: Josef Prazak, MD, PhD, University Hospital Inselspital, Berne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University Hospital Inselspital, Berne
• ClinicalTrials.gov Identifier: NCT05236283
• Other Study ID Numbers: 2021-02302
• First Posted: Feb 11, 2022
• Last Update Posted: Feb 11, 2022
• Last Verified: Feb 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Bacteremia

Study Results

No Results Posted as of Feb 11, 2022